Loading…
Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis
ABSTRACT Objective: To identify determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. By considering the year of the introduction of weekly bisphosphonates important additional information is obtained. Methods: New female users of daily or weekly alendronate...
Saved in:
| Published in: | Current medical research and opinion 2008-05, Vol.24 (5), p.1337-1344 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c427t-b8ead039512ad6f68f2f0b6f09d6746e3347a19552660c57a3b1a6c57b58b0ae3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c427t-b8ead039512ad6f68f2f0b6f09d6746e3347a19552660c57a3b1a6c57b58b0ae3 |
| container_end_page | 1344 |
| container_issue | 5 |
| container_start_page | 1337 |
| container_title | Current medical research and opinion |
| container_volume | 24 |
| creator | Penning-van Beest, Fernie J. A. Erkens, Joëlle A. Olson, M. Herings, Ron M. C. |
| description | ABSTRACT
Objective: To identify determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. By considering the year of the introduction of weekly bisphosphonates important additional information is obtained.
Methods: New female users of daily or weekly alendronate or risedronate between 1999 and 2004, aged ≥ 45 years were identified from PHARMO RLS, including drug-dispensing and hospitalisation data of > 2 million residents of the Netherlands. One-year compliance with bisphosphonates was measured using the Medication Possession Ratio (MPR). To identify determinants of non-compliance, non-compliant women (MPR |
| doi_str_mv | 10.1185/030079908X297358 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1185_030079908X297358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70735598</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-b8ead039512ad6f68f2f0b6f09d6746e3347a19552660c57a3b1a6c57b58b0ae3</originalsourceid><addsrcrecordid>eNp9kMuL1TAUh4MoznV070qKC3fVk6Z56UrGJwy4UXAj4bRNuBnapCYpl_nvzeVeGBzQRUgOvwcnHyHPKbymVPE3wACk1qB-dloyrh6QHe0la3sl5UOyO8pt1fkFeZLzDQDtlNaPyQVVTIGmsCO_Pthi0-IDhpKb6JoQQzvGZZ09htE2B1_2zeDzuo_HE7DY3PjQHOJiw0ldYy51iCtuGeemTjauMcXs81PyyOGc7bPzfUl-fPr4_epLe_3t89er99ft2HeytIOyOAHTnHY4CSeU6xwMwoGehOyFZayXSDXnnRAwcolsoCjqY-BqALTskrw69a4p_t5sLmbxebTzjMHGLRsJlQ7Xqhpf3jPexC2FupvpKknFOgHVBCfTWD-Rk3VmTX7BdGsomCN3c597jbw4927DYqe7wBl0Nbw7GXxwMS14iGmeTMHbOSaXKmqfDftP_du_0nuLc9mPmOzd_v8M_wE_IaRh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>207983260</pqid></control><display><type>article</type><title>Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Penning-van Beest, Fernie J. A. ; Erkens, Joëlle A. ; Olson, M. ; Herings, Ron M. C.</creator><creatorcontrib>Penning-van Beest, Fernie J. A. ; Erkens, Joëlle A. ; Olson, M. ; Herings, Ron M. C.</creatorcontrib><description>ABSTRACT
Objective: To identify determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. By considering the year of the introduction of weekly bisphosphonates important additional information is obtained.
Methods: New female users of daily or weekly alendronate or risedronate between 1999 and 2004, aged ≥ 45 years were identified from PHARMO RLS, including drug-dispensing and hospitalisation data of > 2 million residents of the Netherlands. One-year compliance with bisphosphonates was measured using the Medication Possession Ratio (MPR). To identify determinants of non-compliance, non-compliant women (MPR < 50%) were compared to compliant women (MPR ≥ 80%). The effect of patient age, prescriber, initial dosing regimen, gastrointestinal adverse events, co-medication and fractures on non-compliance was investigated.
Results: The study cohort included 8822 new users of bisphosphonates, of whom 5079 (58%) were compliant and 2720 (31%) were non-compliant after 1 year. Only 1023 women (11%) had a MPR between ≥ 50% and < 80%. Daily dosing at start, increased number of co-medications and new use of intestinal agents in the year after starting bisphosphonates were independently associated with an increased odds of non-compliance. In contrast, higher age, first prescription from a specialist, osteoporosis related hospitalisation and use of NSAIDs in the year preceding bisphosphonate therapy decreased the odds of non-compliance.
Conclusion: This study revealed several determinants of non-compliance with bisphosphonates, the best controllable being the type of initial bisphosphonate, with daily dosing leading to more non-compliance than weekly dosing. However, compliance for both regimens is suboptimal, pointing to an unmet medical need.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/030079908X297358</identifier><identifier>PMID: 18380910</identifier><identifier>CODEN: CMROCX</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject><![CDATA[Aged ; Alendronate - administration & dosage ; Analysis of Variance ; Bisphosphonates ; Bone Density - drug effects ; Co-medication ; Cohort Studies ; Databases, Factual ; Determinants ; Diphosphonates - administration & dosage ; Dose-Response Relationship, Drug ; Dosing frequency ; Drug Administration Schedule ; Etidronic Acid - administration & dosage ; Etidronic Acid - analogs & derivatives ; Female ; Humans ; Logistic Models ; Middle Aged ; Netherlands ; Non-compliance ; Osteoporosis ; Osteoporosis, Postmenopausal - diagnosis ; Osteoporosis, Postmenopausal - drug therapy ; Osteoporosis, Postmenopausal - epidemiology ; Patient Compliance - statistics & numerical data ; Probability ; Prognosis ; Retrospective Studies ; Risedronic Acid ; Risk Factors ; Severity of Illness Index ; Treatment Outcome ; Treatment Refusal - statistics & numerical data]]></subject><ispartof>Current medical research and opinion, 2008-05, Vol.24 (5), p.1337-1344</ispartof><rights>2008 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted 2008</rights><rights>Copyright Librapharm May 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-b8ead039512ad6f68f2f0b6f09d6746e3347a19552660c57a3b1a6c57b58b0ae3</citedby><cites>FETCH-LOGICAL-c427t-b8ead039512ad6f68f2f0b6f09d6746e3347a19552660c57a3b1a6c57b58b0ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18380910$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Penning-van Beest, Fernie J. A.</creatorcontrib><creatorcontrib>Erkens, Joëlle A.</creatorcontrib><creatorcontrib>Olson, M.</creatorcontrib><creatorcontrib>Herings, Ron M. C.</creatorcontrib><title>Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>ABSTRACT
Objective: To identify determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. By considering the year of the introduction of weekly bisphosphonates important additional information is obtained.
Methods: New female users of daily or weekly alendronate or risedronate between 1999 and 2004, aged ≥ 45 years were identified from PHARMO RLS, including drug-dispensing and hospitalisation data of > 2 million residents of the Netherlands. One-year compliance with bisphosphonates was measured using the Medication Possession Ratio (MPR). To identify determinants of non-compliance, non-compliant women (MPR < 50%) were compared to compliant women (MPR ≥ 80%). The effect of patient age, prescriber, initial dosing regimen, gastrointestinal adverse events, co-medication and fractures on non-compliance was investigated.
Results: The study cohort included 8822 new users of bisphosphonates, of whom 5079 (58%) were compliant and 2720 (31%) were non-compliant after 1 year. Only 1023 women (11%) had a MPR between ≥ 50% and < 80%. Daily dosing at start, increased number of co-medications and new use of intestinal agents in the year after starting bisphosphonates were independently associated with an increased odds of non-compliance. In contrast, higher age, first prescription from a specialist, osteoporosis related hospitalisation and use of NSAIDs in the year preceding bisphosphonate therapy decreased the odds of non-compliance.
Conclusion: This study revealed several determinants of non-compliance with bisphosphonates, the best controllable being the type of initial bisphosphonate, with daily dosing leading to more non-compliance than weekly dosing. However, compliance for both regimens is suboptimal, pointing to an unmet medical need.</description><subject>Aged</subject><subject>Alendronate - administration & dosage</subject><subject>Analysis of Variance</subject><subject>Bisphosphonates</subject><subject>Bone Density - drug effects</subject><subject>Co-medication</subject><subject>Cohort Studies</subject><subject>Databases, Factual</subject><subject>Determinants</subject><subject>Diphosphonates - administration & dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Dosing frequency</subject><subject>Drug Administration Schedule</subject><subject>Etidronic Acid - administration & dosage</subject><subject>Etidronic Acid - analogs & derivatives</subject><subject>Female</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Middle Aged</subject><subject>Netherlands</subject><subject>Non-compliance</subject><subject>Osteoporosis</subject><subject>Osteoporosis, Postmenopausal - diagnosis</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Osteoporosis, Postmenopausal - epidemiology</subject><subject>Patient Compliance - statistics & numerical data</subject><subject>Probability</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risedronic Acid</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Treatment Refusal - statistics & numerical data</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp9kMuL1TAUh4MoznV070qKC3fVk6Z56UrGJwy4UXAj4bRNuBnapCYpl_nvzeVeGBzQRUgOvwcnHyHPKbymVPE3wACk1qB-dloyrh6QHe0la3sl5UOyO8pt1fkFeZLzDQDtlNaPyQVVTIGmsCO_Pthi0-IDhpKb6JoQQzvGZZ09htE2B1_2zeDzuo_HE7DY3PjQHOJiw0ldYy51iCtuGeemTjauMcXs81PyyOGc7bPzfUl-fPr4_epLe_3t89er99ft2HeytIOyOAHTnHY4CSeU6xwMwoGehOyFZayXSDXnnRAwcolsoCjqY-BqALTskrw69a4p_t5sLmbxebTzjMHGLRsJlQ7Xqhpf3jPexC2FupvpKknFOgHVBCfTWD-Rk3VmTX7BdGsomCN3c597jbw4927DYqe7wBl0Nbw7GXxwMS14iGmeTMHbOSaXKmqfDftP_du_0nuLc9mPmOzd_v8M_wE_IaRh</recordid><startdate>200805</startdate><enddate>200805</enddate><creator>Penning-van Beest, Fernie J. A.</creator><creator>Erkens, Joëlle A.</creator><creator>Olson, M.</creator><creator>Herings, Ron M. C.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>200805</creationdate><title>Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis</title><author>Penning-van Beest, Fernie J. A. ; Erkens, Joëlle A. ; Olson, M. ; Herings, Ron M. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-b8ead039512ad6f68f2f0b6f09d6746e3347a19552660c57a3b1a6c57b58b0ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Alendronate - administration & dosage</topic><topic>Analysis of Variance</topic><topic>Bisphosphonates</topic><topic>Bone Density - drug effects</topic><topic>Co-medication</topic><topic>Cohort Studies</topic><topic>Databases, Factual</topic><topic>Determinants</topic><topic>Diphosphonates - administration & dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Dosing frequency</topic><topic>Drug Administration Schedule</topic><topic>Etidronic Acid - administration & dosage</topic><topic>Etidronic Acid - analogs & derivatives</topic><topic>Female</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Middle Aged</topic><topic>Netherlands</topic><topic>Non-compliance</topic><topic>Osteoporosis</topic><topic>Osteoporosis, Postmenopausal - diagnosis</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Osteoporosis, Postmenopausal - epidemiology</topic><topic>Patient Compliance - statistics & numerical data</topic><topic>Probability</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risedronic Acid</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Treatment Refusal - statistics & numerical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Penning-van Beest, Fernie J. A.</creatorcontrib><creatorcontrib>Erkens, Joëlle A.</creatorcontrib><creatorcontrib>Olson, M.</creatorcontrib><creatorcontrib>Herings, Ron M. C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Penning-van Beest, Fernie J. A.</au><au>Erkens, Joëlle A.</au><au>Olson, M.</au><au>Herings, Ron M. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2008-05</date><risdate>2008</risdate><volume>24</volume><issue>5</issue><spage>1337</spage><epage>1344</epage><pages>1337-1344</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><coden>CMROCX</coden><abstract>ABSTRACT
Objective: To identify determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. By considering the year of the introduction of weekly bisphosphonates important additional information is obtained.
Methods: New female users of daily or weekly alendronate or risedronate between 1999 and 2004, aged ≥ 45 years were identified from PHARMO RLS, including drug-dispensing and hospitalisation data of > 2 million residents of the Netherlands. One-year compliance with bisphosphonates was measured using the Medication Possession Ratio (MPR). To identify determinants of non-compliance, non-compliant women (MPR < 50%) were compared to compliant women (MPR ≥ 80%). The effect of patient age, prescriber, initial dosing regimen, gastrointestinal adverse events, co-medication and fractures on non-compliance was investigated.
Results: The study cohort included 8822 new users of bisphosphonates, of whom 5079 (58%) were compliant and 2720 (31%) were non-compliant after 1 year. Only 1023 women (11%) had a MPR between ≥ 50% and < 80%. Daily dosing at start, increased number of co-medications and new use of intestinal agents in the year after starting bisphosphonates were independently associated with an increased odds of non-compliance. In contrast, higher age, first prescription from a specialist, osteoporosis related hospitalisation and use of NSAIDs in the year preceding bisphosphonate therapy decreased the odds of non-compliance.
Conclusion: This study revealed several determinants of non-compliance with bisphosphonates, the best controllable being the type of initial bisphosphonate, with daily dosing leading to more non-compliance than weekly dosing. However, compliance for both regimens is suboptimal, pointing to an unmet medical need.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>18380910</pmid><doi>10.1185/030079908X297358</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-7995 |
| ispartof | Current medical research and opinion, 2008-05, Vol.24 (5), p.1337-1344 |
| issn | 0300-7995 1473-4877 |
| language | eng |
| recordid | cdi_crossref_primary_10_1185_030079908X297358 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Aged Alendronate - administration & dosage Analysis of Variance Bisphosphonates Bone Density - drug effects Co-medication Cohort Studies Databases, Factual Determinants Diphosphonates - administration & dosage Dose-Response Relationship, Drug Dosing frequency Drug Administration Schedule Etidronic Acid - administration & dosage Etidronic Acid - analogs & derivatives Female Humans Logistic Models Middle Aged Netherlands Non-compliance Osteoporosis Osteoporosis, Postmenopausal - diagnosis Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - epidemiology Patient Compliance - statistics & numerical data Probability Prognosis Retrospective Studies Risedronic Acid Risk Factors Severity of Illness Index Treatment Outcome Treatment Refusal - statistics & numerical data |
| title | Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A30%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determinants%20of%20non-compliance%20with%20bisphosphonates%20in%20women%20with%20postmenopausal%20osteoporosis&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Penning-van%20Beest,%20Fernie%20J.%20A.&rft.date=2008-05&rft.volume=24&rft.issue=5&rft.spage=1337&rft.epage=1344&rft.pages=1337-1344&rft.issn=0300-7995&rft.eissn=1473-4877&rft.coden=CMROCX&rft_id=info:doi/10.1185/030079908X297358&rft_dat=%3Cproquest_cross%3E70735598%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c427t-b8ead039512ad6f68f2f0b6f09d6746e3347a19552660c57a3b1a6c57b58b0ae3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=207983260&rft_id=info:pmid/18380910&rfr_iscdi=true |